Atorvastatin in Active Vitiligo
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02432534 |
Recruitment Status :
Completed
First Posted : May 4, 2015
Last Update Posted : February 5, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition:
Non segmental and active vitiligo of adulthood.
Main objective:
To evaluate the efficacy of a daily treatment with atorvastatin 80mg/d combined to UVB compared to UVB alone in active vitiligo after 6 months of treatment.
Methods:
Prospective interventional bicentric study with evaluation blinded to the treatment received.
Inclusion criteria:
Patients from 18 to 75 year-old with active non segmental vitiligo. Active is defined by the apparition or the modification of vitiligo lesions with the past 3 months and under Wood's lamp examination hypochromic borders and/or spotty depigmentation.
Interventions:
After central randomization
- Arm A : atorvastatin 40mg/d for 1 months then 80mg/d for 5 months combined with twice weekly narrowband UVB treatment for 6 months.
- Arm B: with twice weekly narrowband UVB treatment for 6 months.
Evaluation:
Main criteria: Decrease of VASI score expressed in percentage Secondary criteria: Decrease of VETF score expressed in percentage. Variation of PGA and DLQI scores. Clinical and biological tolerance. Variation of CXCL10 levels in the serum.
Length of the study:
Inclusion period: 12 months. Length of treatment: 6 months. Statistical analyses and drafting the article: 6 months. Total length: 24 months.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Vitiligo | Drug: Atorvastatin Other: UVB | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 28 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Atorvastatin in Active Vitiligo: a Bicentric Prospective Randomized Trial |
Actual Study Start Date : | May 2015 |
Actual Primary Completion Date : | February 2017 |
Actual Study Completion Date : | December 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: UVB + treatement
The patients will be treated with the combination of oral atorvastatin and NBUVB phototherapy twice a week for 6 months.
|
Drug: Atorvastatin
The patients will be treated with the combination of oral atorvastatin and NBUVB phototherapy twice a week for 6 months. The initial starting dose of the oral atorvastatin will be 40mg daily and after 1 month, if tolerated clinically and biologically following blood tests, the dose will be increased to 80mg daily.
Other Name: UVB |
UVB
The patients will be receiving only NB-UVB phototherapy twice a week for 6 months.
|
Other: UVB
The patients will be receiving only NB-UVB phototherapy twice a week for 6 months. |
- Percentage of decrease in Vitiligo Area Scoring Index (VASI) score [ Time Frame: 4 times (baseline, 1 month, 3 month and 6 month) ]Percentage of decrease in Vitiligo Area Scoring Index (VASI) score between baseline and 6 months after commencement of the study. In the VASI assessment, the body is separated into five sites: hands, upper extremities, trunk, lower extremities and feet. The extent of residual depigmentation is expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. The VASI score is then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the surface of the lesions of all body sites together.
- VETF [ Time Frame: 4 times (baseline, 1 month, 3 month and 6 month) ]Percentage of decrease in Vitiligo European Task Score (VETF) score between baseline and 6 months after commencement of the study.
- PGA [ Time Frame: 4 times (baseline, 1 month, 3 month and 6 month) ]Physician global assessment (PGA). Treatment response will be graded as excellent (76 - 100%), moderate (51 - 75%), Mild (26 - 50%), minimal (1 - 25%) or no response.
- Adverse event [ Time Frame: 4 times (baseline, 1 month, 3 month and 6 month) ]Description of potential side effects using clinical evaluation and biology. Clinical and biological tolerability of high dose of oral atorvastatin will be recorded.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Active non-segmental vitiligo defined by
- Non- segmental vitiligo with new patches or extension of old lesions during the last 3 months AND
- Presence of hypochromic aspect under Wood's lamp examination and/or perifollicular hypopigmentation under Wood's lamp examination
- Patient requiring a treatment by UVB
- Signed informed consent document
- Patient registered to the French Social Security
Exclusion Criteria:
- - Segmental or mixed vitiligo
- Pregnant (urinary pregnancy test will be done) or lactating patients
- Allergy to statin medications
- Use of statin or fibrate medications due to cardiac risks
- Use of statin medications in the past 8 weeks
- Use of any medications contraindicated with use of statin medications
- Use of vitiligo treatments (both topicals and phototherapy) in the past 4 weeks
- Treatment with immunomodulating oral medications in the past 4 weeks
- Hepatic disease and/or dysfunction
- Renal dysfunction
- Personal or familial history of myopathy or personal history of rhabdomyolysis or elevated baseline creatinine kinase
- Alcohol or drug abuse
- Untreated hypothyroidism
- Personal history of skin cancer
- Any other clinically significant findings that, in the opinion of the Principal Investigator, might interfere with study evaluations or pose a risk to subject safety during the study.
- Patients assessed to be uncooperative
- Participants in other clinical studies

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02432534
France | |
CHU de Nice | |
Nice, Alpes-Maritimes, France, 06001 | |
Indonesia | |
National Skin center - 1 Mandalay Rd | |
Bedok, Singapore, Indonesia, 308205 |
Principal Investigator: | Passeron Thierry, PhD | Centre Hospitalier Universitaire de Nice | |
Principal Investigator: | Chuah Sai Yee, Ph | Singapour |
Responsible Party: | Centre Hospitalier Universitaire de Nice |
ClinicalTrials.gov Identifier: | NCT02432534 |
Other Study ID Numbers: |
15-AOI-01 |
First Posted: | May 4, 2015 Key Record Dates |
Last Update Posted: | February 5, 2018 |
Last Verified: | March 2017 |
Vitiligo Hypopigmentation Pigmentation Disorders Skin Diseases Atorvastatin Anticholesteremic Agents |
Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Enzyme Inhibitors |